Open AccessP1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R‐CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON‐GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
Author(s) -
Li C.,
Geng H.,
Zong X.,
Zhou J.,
Zhang Y.,
Li J.,
Jia S.,
Wu D.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847604.18059.09
Subject(s) - medicine , regimen , vincristine , diffuse large b cell lymphoma , rituximab , oncology , phases of clinical research , adverse effect , lymphoma , cyclophosphamide , clinical trial , gastroenterology , surgery , chemotherapy